{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:06:15Z","timestamp":1767211575250,"version":"3.46.0"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-24683593","2020R1A2C1009224"],"award-info":[{"award-number":["RS-2025-24683593","2020R1A2C1009224"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HR16C0001","RS-2024-00335936"],"award-info":[{"award-number":["HR16C0001","RS-2024-00335936"]}]},{"name":"Government-wide R&D Fund project for infectious disease research (GFID), Republic of Korea","award":["HG22C0024","KH124685"],"award-info":[{"award-number":["HG22C0024","KH124685"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Rosuvastatin and atorvastatin are indicated for cardiovascular protection in patients with type 2 diabetes (T2D) but may differ in clinical effectiveness and safety. This study compared real-world cardiovascular and safety outcomes associated with rosuvastatin versus atorvastatin in patients with T2D, with an emphasis on older adults. Methods: This retrospective cohort study used electronic health records from 10 Korean hospitals standardized to the Common Data Model. Adults (\u226518 years) with T2D who were newly prescribed rosuvastatin or atorvastatin were included. After propensity score matching, primary outcomes (myocardial infarction [MI], heart failure, stroke, cardiac arrest, and in-hospital death), secondary outcomes (peripheral arterial disease [PAD] and glaucoma), and safety outcomes (acute kidney injury, cataract, and myalgia) were compared. Subgroup and sensitivity analyses were conducted among patients aged \u226565 years. Results: Among 49,034 patients (rosuvastatin, 16,123; atorvastatin, 32,911), baseline characteristics were well balanced. Across all participating hospitals, the comparative analyses showed no meaningful differences in cardiovascular or safety outcomes between the two statins. However, among patients aged \u226565 years, rosuvastatin was associated with a higher risk of PAD (hazard ratio [HR] 1.19; 95% confidence interval [CI] 1.03\u20131.38), and this finding was consistent in sensitivity analysis (HR 1.31; 95% CI 1.01\u20131.70). Conclusions: Rosuvastatin and atorvastatin demonstrated comparable cardiovascular effectiveness and safety. Although rosuvastatin was associated with a modestly higher incidence of PAD in older adults, the difference was small. From a clinical perspective, these findings underscore the importance of individualized statin therapy tailored to patient-specific factors such as age, comorbidity, and vascular health. Overall, both statins provide overall therapeutic equivalence for cardiovascular prevention.<\/jats:p>","DOI":"10.3390\/ph18121860","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:17:07Z","timestamp":1764940627000},"page":"1860","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rosuvastatin Versus Atorvastatin for Cardiovascular Disease Risk in Patients with Type 2 Diabetes: A Korean Cohort Study"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6478-7430","authenticated-orcid":false,"given":"Chaeyoon","family":"Kim","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-0232","authenticated-orcid":false,"given":"Junhyuk","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Graduate School of Ajou University, 206, World cup-ro, Yeongtong-gu, Suwon-si 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Graduate School of Ajou University, 206, World cup-ro, Yeongtong-gu, Suwon-si 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohyeon","family":"Park","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalynn","family":"Park","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-5923","authenticated-orcid":false,"given":"Hong-Ah","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02453, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-3287","authenticated-orcid":false,"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Graduate School of Ajou University, 206, World cup-ro, Yeongtong-gu, Suwon-si 16499, Republic of Korea"},{"name":"Department of Biomedical Informatics, Ajou University School of Medicine, 206, World cup-ro, Yeongtong-gu, Suwon-si 16499, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2554-3370","authenticated-orcid":false,"given":"Sandy Jeong","family":"Rhie","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"ref_1","unstructured":"(2025, November 12). American Heart Association. More than Half of U.S. Adults Don\u2019t Know Heart Disease Is Leading Cause of Death, Despite 100-Year Reign. Available online: https:\/\/newsroom.heart.org\/news\/more-than-half-of-u-s-adults-dont-know-heart-disease-is-leading-cause-of-death-despite-100-year-reign."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: Pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/jdi.14042","article-title":"Updates on dyslipidemia in patients with diabetes","volume":"14","author":"Ide","year":"2023","journal-title":"J. Diabetes Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4093\/dmj.2023.0282","article-title":"2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association","volume":"47","author":"Choi","year":"2023","journal-title":"Diabetes Metab. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16208","DOI":"10.20452\/pamw.16208","article-title":"Statins in prevention of thromboembolic events: From seminal studies to recent advances","volume":"132","author":"Undas","year":"2022","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.24304\/kjcp.2021.31.3.198","article-title":"Atherosclerotic cardiovascular disease risk and statin prescription status in Korean adult patients","volume":"31","author":"Kim","year":"2021","journal-title":"Korean J. Clin. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jare.2024.12.020","article-title":"Advances in statin adverse reactions and the potential mechanisms: A systematic review","volume":"76","author":"Zeng","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/HCO.0000000000001003","article-title":"Primary prevention statin therapy in older adults","volume":"38","author":"Nanna","year":"2023","journal-title":"Curr. Opin. Cardiol."},{"key":"ref_11","first-page":"1","article-title":"Optimizing Statin Therapy in Older Adults: A Systematic Review of Dosing, Titration, and Combination Strategies","volume":"47","author":"Artner","year":"2025","journal-title":"Geroscience"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12933-022-01524-6","article-title":"Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: A distributed network analysis of 10 real-world databases","volume":"21","author":"Seo","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Choi, J.Y., Choi, C.U., Choi, B.G., Park, Y., Kang, D.O., Jang, W.Y., Kim, W., Na, J.O., Kim, J.W., and Kim, E.J. (2021). New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC Pharmacol. Toxicol., 22.","DOI":"10.1186\/s40360-021-00476-z"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103784","DOI":"10.1016\/j.numecd.2024.10.022","article-title":"Assessing real-world effectiveness of atorvastatin in patients with type 2 diabetes mellitus for the primary prevention of cardiovascular events","volume":"35","author":"Kim","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e075837","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease","volume":"383","author":"Lee","year":"2023","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-2840-4-7","article-title":"Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: Results from the URANUS study","volume":"4","author":"Berne","year":"2005","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.13063\/2327-9214.1110","article-title":"Transforming the premier perspective hospital database into the observational medical out-comes partnership (omop) common data model","volume":"2","author":"Makadia","year":"2014","journal-title":"Egems"},{"key":"ref_18","first-page":"574","article-title":"Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers","volume":"216","author":"Hripcsak","year":"2015","journal-title":"Stud. Health Technol. Inform."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e067731","DOI":"10.1136\/bmj-2021-067731","article-title":"Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes","volume":"376","author":"Hodkinson","year":"2022","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1177\/2047487319868035","article-title":"Impact of rosuvastatin versus atorvastatin on coronary atherosclerotic plaque volume","volume":"27","author":"Kumar","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Singh, S., Tantry, U., Bliden, K., Ishaq, S.M.M., Abuzahra, M., and Gurbel, P.A. (2024). Meta-analysis of rosuvastatin vs atorvastatin in patients with cardiovascular disease. J. Am. Coll. Cardiol., 83.","DOI":"10.1016\/S0735-1097(24)03215-7"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Werida, R., Khairat, I., and Khedr, N.F. (2021). Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. Biomed. Pharmacother., 135.","DOI":"10.1016\/j.biopha.2020.111179"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.7326\/M24-0178","article-title":"Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin: A Multi-database Cohort Study","volume":"177","author":"Zhou","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/FJC.0b013e318294998d","article-title":"Atorvastatin active metabolite inhibits oxidative modification of small dense LDL","volume":"62","author":"Jacob","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0735-1097(24)03283-2","article-title":"Atorvastatin active hydroxylated metabolites inhibit lipoprotein(a) oxidation compared to rosuvastatin in vitro","volume":"83","author":"Sherratt","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kokina, B., Trusinskis, K., Lap\u0161ovs, M., Karantajere, M., Knoka, E., Caunite, L., Jegere, S., Narbute, I., Sondore, D., and Kumsars, I. (2024). Plaque lipid content reduction with atorvastatin versus rosuvastatin. J. Am. Coll. Cardiol., 83.","DOI":"10.1016\/S0735-1097(24)03268-6"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Khan, S., Huda, B., Bhurka, F., Patnaik, R., and Banerjee, Y. (2025). Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-\u03baB, NLRP3 Inflammasome, and Cytokine Regulatory Axes. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178429"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jacl.2011.08.006","article-title":"The differential effect of statins on oxidative stress and endothelial function: Atorvastatin versus pravastatin","volume":"6","author":"Murrow","year":"2012","journal-title":"J. Clin. Lipidol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.jacc.2020.02.059","article-title":"Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease","volume":"75","author":"Duran","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","unstructured":"GBD 2019 Peripheral Artery Disease Collaborators (2023). Global burden of peripheral artery disease and its risk factors, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Glob. Health, 11, e1553\u2013e1565."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-031-26576-1_3","article-title":"Chronic inflammation as an underlying mechanism of ageing and ageing-related diseases","volume":"103","author":"Chung","year":"2023","journal-title":"Subcell Biochem."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Pacinella, G., Ciaccio, A.M., and Tuttolomondo, A. (2022). Endothelial dysfunction and chronic inflammation: The cornerstones of vascular alterations in age-related diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415722"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12933-020-01130-4","article-title":"Diabetes as a risk factor for incident peripheral arterial disease in women compared to men: A systematic review and meta-analysis","volume":"19","author":"Chan","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and Risk of Amputation in Patients with Diabetes Mellitus and Peripheral Artery Disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12933-024-02226-x","article-title":"Risk factors for and risk of all-cause and atherosclerotic cardiovascular disease mortality in people with type 2 diabetes and peripheral artery disease: An observational, register-based cohort study","volume":"23","author":"Avdic","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_36","first-page":"1113","article-title":"Comparative Study Between the Effects of High Doses of Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction","volume":"38","author":"Elhadad","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4103\/0976-500X.162011","article-title":"Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome","volume":"6","author":"Khurana","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_38","unstructured":"American Diabetes Association Professional Practice Committee (2024). Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S1\u2013S4."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: A tool for detecting confounding and bias","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jbi.2016.12.005","article-title":"Accuracy of an automated knowledge base for identifying drug adverse reactions","volume":"66","author":"Voss","year":"2017","journal-title":"J. Biomed. Inform."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/12\/1860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T13:43:51Z","timestamp":1764942231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/12\/1860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ph18121860"],"URL":"https:\/\/doi.org\/10.3390\/ph18121860","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]}}}